PTC Therapeutics, Inc.
PTCT
Classement en actions
#3326
PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the... PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. Its robust pipeline encompasses both commercialized therapies and a variety of experimental drug candidates, spanning all stages of development—from early research and preclinical studies to clinical trials—with a primary focus on addressing various rare disease indications. Among its commercialized products, PTC Therapeutics provides Translarna and Emflaza, offering therapeutic options for Duchenne muscular dystrophy patients in the European Economic Area and the United States. Translarna also addresses nonsense mutation Duchenne muscular dystrophy in Brazil and Russia. The company additionally commercializes Tegsedi and Waylivra for various rare conditions throughout Latin America and the Caribbean. Furthermore, in Brazil, PTC Therapeutics distributes Evrysdi as a treatment for spinal muscular atrophy (SMA) in patients aged two months and older. Leveraging its proprietary splicing platform, the company is also actively developing PTC518, a promising therapeutic candidate aimed at treating Huntington's disease. To bolster its research and development capabilities, PTC Therapeutics has established strategic collaborations, including partnerships with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation, focusing on advancing drug discovery and development research, particularly in regenerative medicine. Additionally, it collaborates with Akcea Therapeutics, Inc. for the commercialization of Tegsedi and Waylivra in the Latin America and Caribbean region. Established in 1998, PTC Therapeutics, Inc. maintains its corporate headquarters in South Plainfield, New Jersey.
Prix de l'action
$62.72
Capitalisation boursière
$5.23B
Changement (1 jour)
1.94%
Changement (1 an)
-8.25%
Pays
US
Échange PTC Therapeutics, Inc. (PTCT)
Catégorie
Healthcare
Bénéfices pour PTC Therapeutics, Inc. (PTCT)
Bénéfices en Jun 2026 TTM : $-67.07M
Selon les derniers rapports financiers de PTC Therapeutics, Inc., les bénéfices actuels de l'entreprise sont de $-67.07M. En 2023, l'entreprise a réalisé un bénéfice de $-696.11M, une diminution par rapport à celui de 2022 qui était de $-587.49M. Les bénéfices affichés sur cette page correspondent aux bénéfices avant intérêts et impôts, appelés aussi EBIT.
Historique des bénéfices pour PTC Therapeutics, Inc. de 2011 à 2026
Bénéfices à la fin de chaque année
| Année | Bénéfices | Changez |
|---|---|---|
| 2026 (TTM) | $-67.07M | -81.53% |
| 2024 | $-363.12M | -47.84% |
| 2023 | $-696.11M | 18.49% |
| 2022 | $-587.49M | 13.34% |
| 2021 | $-518.34M | 28.64% |
| 2020 | $-402.93M | 67.94% |
| 2019 | $-239.93M | 87.28% |
| 2018 | $-128.11M | 64.95% |
| 2017 | $-77.67M | -45.13% |
| 2016 | $-141.54M | -16.72% |
| 2015 | $-169.96M | 72.64% |
| 2014 | $-98.45M | 90.88% |
| 2013 | $-51.57M | 96.58% |
| 2012 | $-26.24M | -191.73% |
| 2011 | $28.60M | 0.00% |
Bénéfices des entreprises similaires ou concurrentes
| Entreprise | Bénéfices | Différence de bénéfices | Pays |
|---|---|---|---|
| $5.27B | -7,964.30% |
US
|
|
| $-3.09B | 4,502.38% |
US
|
|
| $-4.02B | 5,887.71% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -3,008.21% |
NL
|
